Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Announces First Participant Trial of Wholly-Owned Lymphedema LYT-100","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Genentech\u2019s Esbriet pirfenidone","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","amount":"$35.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Roche\u2019s Esbriet (Pirfenidone) for Unclassifiable Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pirfenidone Reduces Scar Tissue in Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"National Institute for Health Research","sponsor":"Manchester University NHS Foundation Trust","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pirfenidone Could Offer \u2018viable\u2019 Heart Failure Treatment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Avalyn Pharma","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches First Generic Pirfenidone in US for Patients With Idiopathic Pulmonary Fibrosis, Growing Its Respiratory Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics to Participate in \u201cDrug Development in Pulmonary Medicine\u201d Panel Discussion at 2022 BTIG Biotechnology Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Pirfenidone

    Menu

    Pirfenidone

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Avalyn Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

              Details:

              Avalyn will use the funds for the development of its portfolio of inhalation therapies for interstitial lung disease that improve upon currently approved medications, and advance lead clinical assets, AP01 (pirfenidone) and AP02 (nintedanib), into mid-stage clinical trials.

              Lead Product(s): Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AP01

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Avalyn Pharma

              Deal Size: $175.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing September 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Avalyn Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis

              Details:

              AP01 (pirfenidone) is a small molecule shown to inhibit fibroblast differentiation and extracellular matrix (ECM) production. It is being investigated in adults with pulmonary fibrosis.

              Lead Product(s): Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AP01

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              aTyr Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

              Details:

              ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis.

              Lead Product(s): Efzofitimod,Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Blade Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022

              Details:

              BLD-0409 (cudetaxestat) was well tolerated and showed no reports of treatment-related serious adverse events, including when co-administered with either pirfenidone or nintedanib, in healthy volunteers.

              Lead Product(s): Cudetaxestat,Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Blade Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

              Details:

              BLD-0409 (cudetaxestat), a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial in patients with idiopathic pulmonary fibrosis.

              Lead Product(s): Cudetaxestat,Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sandoz B2B

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sandoz Launches First Generic Pirfenidone in US for Patients With Idiopathic Pulmonary Fibrosis, Growing Its Respiratory Portfolio

              Details:

              Pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech’s Esbriet®*, to treat patients with idiopathic pulmonary fibrosis, a progressive disease that causes irreversible lung scarring and makes it difficult to breathe.

              Lead Product(s): Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Pirfenidone-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Blade Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

              Details:

              U.S. FDA provides feedback necessary to proceed into a phase 2 proof of concept (PoC)/dose ranging study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in patients with idiopathic pulmonary fibrosis (IPF).

              Lead Product(s): Cudetaxestat,Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Blade Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

              Details:

              New data from a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor co-administered with either of two approved drugs for IPF (pirfenidone and nintedanib) will be presented.

              Lead Product(s): Cudetaxestat,Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Biotech Acquisition Company

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              National Institute for Health Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pirfenidone Could Offer ‘viable’ Heart Failure Treatment

              Details:

              The trial, funded by the National Institute for Health Research (NIHR), found that pirfenidone could offer a viable treatment for heart failure with preserved ejection fraction.

              Lead Product(s): Pirfenidone

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Esbriet

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Manchester University NHS Foundation Trust

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Avalyn Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial

              Details:

              AP01 was safe and well tolerated at both doses. Flu-like symptoms and GI adverse events most commonly attributed to oral pirfenidone were seen in less than 10% of patients treated with AP01.

              Lead Product(s): Pirfenidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AP01

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY